Scroll To Top
News

Nuke 'Em

Nuke 'Em

Microwave_0

A new examination of Sustiva- and Viramune-based triple-drug regimens has shown that it isn't the choice between the two nonnucleoside analogs that predicts long-term viral control among treatment-naive HIVers but rather the accompanying nucleosides. The review, published in the April 6 issue of the Journal of Acquired Immune Deficiency Syndromes, shows that both Sustiva and Viramune are most successful when paired with two newer nukes than with such older combinations as Zerit plus Epivir or Videx plus Viread.

Advocate Channel - Queer CutsOut Magazine - Fellow Travelers

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.